CN
Home
Home
About Us
About Us
Ark Overview
Our Team
Our History
Our Culture
Our Advisors
Research
Research
Pipeline
Pipeline
Media
Media
Ark News
Career
Career
Contact Us
Contact Us
Investor relations
Investor relations
Corporate Governance
Board Members
Announcements and Circulars
Stock Information
IR
Home
About Us
Ark Overview
Our Team
Our History
Our Culture
Our Advisors
Research
Pipeline
Media
Ark News
Career
Contact Us
Investor relations
Corporate Governance
Board Members
Announcements and Circulars
Stock Information
IR
Ark News
2022
2021
2020
2019
2018
2017
2016
2015
2014
2018-11-01
Ark Biosciences Reports Significant Progress of Phase 2 Clinical Trial of Ziresovir for Treatment of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients
2018-11-01
2018-08-22
Ark Biosciences to Present Efficacy Data on Novel Ziresovir at an International Conference
2018-08-22
2018-08-13
Ark scientists and international KOLs publish research articles on antiviral drug resistance in acute and chronic infections
For full article:https://doi.org/10.1016/j.antiviral.2018.07.020
2018-07-25
Ark Biosciences Licenses a Clinical Stage Drug for Treatment of Idiopathic Pulmonary Fibrosis
ARK BIOSCIENCES (Ark) announced today that the company has entered into a license agreement with F. Hoffmann-Roche Ltd (Roche) to transfer a potential new standard-of-care treatment for idiopathic pulmonary fibrosis to Ark. The new agent has already completed its first-in-human clinical trial.
Prev
1
Next
TOP
Home
Tel
Top
TOP
Telephone：
Address：
E-mail：
CN
